TruSpine Technolgs. - Further re: Extension of Subscription Date
RNS Number : 1608F
TruSpine Technologies PLC
12 November 2020
 

 

TruSpine Technologies plc

("TruSpine" or the "Company")

 

Further re: Extension of Subscription Date

 

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the spinal (vertebral) stabilisation market, announces that, further to the announcement released by the Company today, the Company and Evrensel Capital Partners Limited have reached an agreement to further extend the deadline for the Subscription Date in relation to the subscription for 694,444 new ordinary shares in the Company at a price of 36 pence per share, to 5 January 2021.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

The Directors of the Company take responsibility for this announcement.

 

Enquiries:

 

TruSpine Technologies Plc

Tel: +44 (0)20 3638 5025

Ian Roberts, CEO




Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti




WH Ireland (Broker)

Tel: +44 (0)20 7220 1666

Adam Pollock




Walbrook PR (Financial PR & IR)

Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001

Anna Dunphy

truspine@walbrookpr.com

 

 

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXKKBBQNBDDDDD ]]>